The potential of patient-derived organoids in precision medicine of biliary tract cancer

Mariana Yáñez-Bartolomé; Teresa Macarulla; Tian V Tian

doi:10.1016/j.xcrm.2023.101294

The potential of patient-derived organoids in precision medicine of biliary tract cancer

Cell Rep Med. 2023 Nov 21;4(11):101294. doi: 10.1016/j.xcrm.2023.101294.

Authors

Mariana Yáñez-Bartolomé¹, Teresa Macarulla¹, Tian V Tian²

Affiliations

¹ Upper Gastrointestinal Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
² Upper Gastrointestinal Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain. Electronic address: tiantian@vhio.net.

Abstract

Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.¹ developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction.

Publication types

Comment

MeSH terms

Biliary Tract Neoplasms* / drug therapy
Biliary Tract Neoplasms* / genetics
Humans
Organoids
Precision Medicine*